Recruiting soon
BTK Inhibitor Zanubrutinib for Chronic Lymphocytic Leukemia in China
What is being collected
Data Collection
Collected from past medical records and data - RetrospectiveWho is being recruted
Over 18 Years
+5 Eligibility Criteria
How is the trial designed
Cohort
Tracking disease incidence in order to identify risk factors and understand disease progression over time.Observational
Study Start: September 2024
Summary
Principal SponsorPeking University People's Hospital
Study ContactShengmiao Yang, MD
Last updated: January 28, 2026Sourced from a government-validated database.Claim as a partner
Study start date: September 1, 2024
Actual date on which the first participant was enrolled.This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China
Official TitleThis is a Multicenter, Retrospective Real-world Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China
Principal SponsorPeking University People's Hospital
Study ContactShengmiao Yang, MD
Last updated: January 28, 2026Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
1000 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Cohort
These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Criteria
5 inclusion criteria required to participate
Patients aged ≥18 years old
Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) requiring treatment (iwCLL [International Workshop on Chronic Lymphocytic Leukemia] criteria)；
Treatment-naïve OR Refractory Recurrence CLL patients who were initiated on BTK inhibitor;
Prior or current use of BTK inhibitor for ≥3 months
Show More Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Study Objectives
Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has no location dataSave this study to your profile to know when the location data is available.
Recruiting soonNo study centers